MarketResearchNest.com adds “Tetanus – Pipeline Review, H2 2017” new report to its research database. The report spread across 71 pages with table and figures in it.
Tetanus – Pipeline Review, H2 2017
Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Tetanus – Pipeline Review, H2 2017, provides an overview of the Tetanus (Infectious Disease) pipeline landscape.
Tetanus is a serious illness caused by Clostridium bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. The predisposing factors include burns, surgical wounds, ear infections, swelling around the injury and infected foot ulcers. Treatment includes antibiotics, sedatives and beta blockers.
Browse full table of contents and data tables at
The Tetanus (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tetanus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 1, 9, 4, 5, 1 and 8 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 2 molecules, respectively.
Tetanus (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co Ltd, Bharat Biotech International Ltd, Biological E Ltd, Cadila Healthcare Ltd, Daiichi Sankyo Company Ltd, GlaxoSmithKline Plc, Green Cross Corp, Indian Immunologicals Ltd, Kaketsuken, LG Chem, Ltd., Sanofi, Sanofi Pasteur SA, Serum Institute of India Ltd, Shantha Biotechnics Pvt Ltd.
Order a Purchase Report Copy at https://www.marketresearchnest.com/purchase.php?reportid=262578
Featured News & Press Releases
Mar 17, 2015: Sanofi: Shantha Will Provide Up To 37 Million Doses Of Shan5
Nov 24, 2014: CanSinotech submitted CTA of “Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed” to CFDA
Nov 10, 2014: Shantha’s Pentavalent Pediatric Vaccine launched in India
May 05, 2014: Shantha’s Pentavalent Pediatric Vaccine prequalified by World Health Organization
May 11, 2011: Sanofi Pasteur Launches Pentaxim In China
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective RandD strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Tetanus (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Tetanus (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Request a sample copy at
More reports on Pipeline Review H2 2017
Estrogen Receptor (ER Alpha Or Estradiol Receptor Or Nuclear Receptor Subfamily 3 Group A Member 1 Or NR3A1 Or ESR1) – Pipeline Review, H2 2017 Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) pipeline Target constitutes close to 22 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The latest report Estrogen Receptor – Pipeline Review, H2 2017, outlays comprehensive information on the Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Get More Details at https://www.marketresearchnest.com/estrogen-receptor-er-alpha-or-estradiol-receptor-or-nuclear-receptor-subfamily-3-group-a-member-1-or-nr3a1-or-esr1—pipeline-review-h2-2017.html .
MarketResearchNest.com is the most comprehensive collection of market research products and service Tetanus on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.
Mr. Jeet Jain